Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 6/2011

01.12.2011 | Mediators, Mechanisms, and Pathways in Tissue Injury (Heinrich Taegtmeyer and Steven Atlas, Section Editors)

Effects of Relaxin on Arterial Dilation, Remodeling, and Mechanical Properties

verfasst von: Kirk P. Conrad, Sanjeev G. Shroff

Erschienen in: Current Hypertension Reports | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Administering relaxin to conscious rats and humans elicits systemic and renal vasodilation. The molecular mechanisms vary according to the duration of relaxin exposure—so-called “rapid” (within minutes) or “sustained” (hours to days) vasodilatory responses—both being endothelium-dependent. Rapid responses are mediated by Gαi/o protein coupling to phosphoinositol-3 kinase/Akt (protein kinase B)–dependent phosphorylation and activation of nitric oxide synthase. Sustained responses are mediated by vascular endothelial and placental growth factors, as well as increases in arterial gelatinase activity. Thus, after hours or days of relaxin treatment, respectively, arterial MMP-9 or MMP-2 hydrolyze “big” endothelin (ET) at a gly-leu bond to form ET1-32, which in turn activates the endothelial ETB receptor/nitric oxide vasodilatory pathway. Administration of relaxin to conscious rats also increases global systemic arterial compliance and passive compliance of select isolated blood vessels such as small renal arteries (SRA). The increase in SRA passive compliance is mediated by both geometric remodeling (outward) and compositional remodeling (decreased collagen). Relaxin-induced geometric remodeling has also been observed in brain parenchymal arteries, and this remodeling appears to be via the activation of peroxisome proliferator–activated receptor-γ. Given the vasodilatory and arterial remodeling properties of relaxin, the hormone may have therapeutic potential in the settings of abnormal pregnancies, heart failure, and pathologies associated with stiffening of arteries.
Literatur
1.
Sherwood OD. Relaxin’s physiological roles and other diverse actions. Endocr Rev. 2004;25:205–34.PubMedCrossRef
2.
Bathgate RA, Samuel CS, Burazin TC, et al. Relaxin: new peptides, receptors and novel actions. Trends Endocrinol Metabol. 2003;14:207–13.CrossRef
3.
Sherwood OD. Relaxin. In: Knobil E, Neill JD, Greenwald GS, Markert CL, Pfaff DW, editors. The physiology of reproduction. 2nd ed. New York: Raven; 1994. p. 861–1008.
4.
Conrad KP. Emerging role of relaxin in the maternal adapations to normal pregnancy: implications for preeclampsia. Semin Nephrol. 2011;31:15–32.PubMedCrossRef
5.
Hisaw FL, Hisaw Jr FL, Dawson AB. Effects of relaxin on the endothelium of endometrial blood vessels in monkeys (Macaca mulatta). Endocrinol. 1967;81:375–85.CrossRef
6.
Dallenbach-Hellweg G, Dawson AB, Hisaw FL. The effect of relaxin on the endometrium of monkeys. Histological and histochemical studies. Am J Anat. 1966;119:61–78.CrossRef
7.
St-Louis J, Massicotte G. Chronic decrease of blood pressure by rat relaxin in spontaneously hypertensive rats. Life Sci. 1985;37:1351–7.PubMedCrossRef
8.
Bani-Sacchi T, Bigazzi M, Bani D, et al. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol. 1995;116:1589–94.PubMed
9.
Conrad KP, Debrah DO, Novak J, et al. Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. Endocrinol. 2004;145:3289–96.CrossRef
10.
Debrah DO, Conrad KP, Danielson LA, Shroff SG. Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response. J Appl Physiol. 2005;98:1013–20.PubMedCrossRef
11.
Debrah DO, Novak J, Matthews JE, et al. Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. Endocrinol. 2006;147:5126–31.CrossRef
12.
Debrah DO, Conrad KP, Jeyabalan A, et al. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension. 2005;46:745–50.PubMedCrossRef
13.
August P, Lindheimer MD. Chronic hypertension and pregnancy. In: Lindheimer MD, Roberts JM, Cunningham GF, editors. Chesley’s hypertensive disorders in pregnancy. 3rd ed. San Diego: Academic; 2009. p. 353–68.CrossRef
14.
Danielson LA, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest. 1999;103:525–33.PubMedCrossRef
15.
Conrad KP. Renal hemodynamics during pregnancy in chronically catheterized, conscious rats. Kidney Int. 1984;26:24–9.PubMedCrossRef
16.
Danielson LA, Kercher LJ, Conrad KP. Impact of gender and endothelin on renal vasodilation and hyperfiltration induced by relaxin in conscious rats. Am J Physiol. 2000;279:R1298–304.
17.
Novak J, Ramirez RJ, Gandley RE, et al. Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats. Am J Physiol. 2002;283:R349–55.
18.
Gandley RE, Conrad KP, McLaughlin MK. Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats. Am J Physiol. 2001;280:R1–7.
19.
van Drongelen J, Pertijs J, Wouterse A et al. Contribution of different local vascular responses to mid-gestational vasodilation. Am J Obstet Gynecol 2011. Eub ahead of print.
20.
van Drongelen J, Ploemen IH, Pertijs J, et al. Aging attenuates the vasodilator response to relaxin. Am J Physiol Heart Circ Physiol. 2011;300:H1609–1615.PubMedCrossRef
21.
Conrad KP, Colpoys MC. Evidence against the hypothesis that prostaglandins are the vasodepressor agents of pregnancy. Serial studies in chronically instrumented, conscious rats. J Clin Invest. 1986;77:236–45.PubMedCrossRef
22.
Danielson LA, Conrad KP. Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. J Clin Invest. 1995;96:482–90.PubMedCrossRef
23.
Novak J, Reckelhoff J, Bumgarner L, et al. Reduced sensitivity of the renal circulation to angiotensin II in pregnant rats. Hypertension. 1997;30:580–4.PubMed
24.
Ferreira VM, Gomes TS, Reis LA, et al. Receptor-induced dilatation in the systemic and intrarenal adaptation to pregnancy in rats. PLoS One. 2009;4:e4845.PubMedCrossRef
25.
Sasser JM, Molnar M, Baylis C. Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats. Hypertension. 2011;58:197–204.PubMedCrossRef
26.
Danielson LA, Conrad KP. Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats. J Appl Physiol. 2003;95:1509–14.PubMed
27.
Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail. 2009;15:182–90.PubMedCrossRef
28.
Perna AM, Masini E, Nistri S, et al. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J. 2005;19:1525–7.PubMed
29.
Erikson MS, Unemori EN. Relaxin clinical trials in systemic sclerosis. In: Tregear GW, Ivell R, Bathgate RA, Wade JD, editors. Proceedings of the Third International Conference on Relaxin and Related Peptides. Dordrecht: Kluwer; 2001. p. 373–81.
30.
Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60:1102–11.PubMedCrossRef
31.
• Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev. 2008;14:321–9. The vascular actions of relaxin may have therapeutic indications for pathologies of pregnancy such as preeclampsia, as well as for disorders in the nonpregnant population, including heart failure. This work is important because it summarizes the rationale and evidence for the use of relaxin as a therapeutic agent in heart failure. PubMedCrossRef
32.
Smith MC, Danielson LA, Conrad KP, Davison JM. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J Am Soc Nephrol. 2006;17:3192–7.PubMedCrossRef
33.
Jeyabalan A, Conrad KP. Renal physiology and pathophysiology in pregnancy. In: Schrier RW, editor. Renal and electrolyte disorders. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 462–518.
34.
Novak J, Danielson LA, Kerchner LJ, et al. Relaxin is essential for renal vasodilation during pregnancy in conscious rats. J Clin Invest. 2001;107:1469–75.PubMedCrossRef
35.
Smith MC, Murdoch AP, Danielson LA, et al. Relaxin has a role in establishing a renal response in pregnancy. Fertil Steril. 2006;86:253–5.PubMedCrossRef
36.
Conrad KP. Possible mechanisms for changes in renal hemodynamics during pregnancy: studies from animal models. Am J Kidney Dis. 1987;9:253–9.PubMed
37.
Rapoport RM, Murad F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP. Circ Res. 1983;52:352–7.PubMed
38.
Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–6.PubMedCrossRef
39.
Conrad KP, Vernier KA. Plasma level, urinary excretion, and metabolic production of cGMP during gestation in rats. Am J Physiol. 1989;257:R847–53.PubMed
40.
Conrad KP, Joffe GM, Kruszyna H, et al. Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J. 1993;7:566–71.PubMed
41.
Gellai M, Fletcher T, Pullen M, Nambi P. Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am J Physiol. 1996;271:R254–261.PubMed
42.
Conrad KP, Gandley RE, Ogawa T, et al. Endothelin mediates renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. Am J Physiol. 1999;276:F767–76.PubMed
43.
Alexander BT, Miller MT, Kassab S, et al. Differential expression of renal nitric oxide synthase isoforms during pregnancy in rats. Hypertension. 1999;33:435–9.PubMed
44.
Novak J, Rajakumar A, Miles TM, Conrad KP. Nitric oxide synthase isoforms in the rat kidney during pregnancy. J Soc Gynecol Investig. 2004;11:280–8.PubMedCrossRef
45.
Smith CA, Santymire B, Erdely A, et al. Renal nitric oxide production in rat pregnancy: role of constitutive nitric oxide synthases. Am J Physiol Renal Physiol. 2010;299:F830–836.PubMedCrossRef
46.
Kerchner LJ, Novak J, Hanley-Yanez K, et al. Evidence against the hypothesis that endothelial endothelin B receptor expression is regulated by relaxin and pregnancy. Endocrinol. 2005;146:2791–7.CrossRef
47.
Dschietzig T, Bartsch C, Richter C, et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res. 2003;92:32–40.PubMedCrossRef
48.
Jeyabalan A, Novak J, Danielson LA, et al. Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res. 2003;93:1249–57.PubMedCrossRef
49.
Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest. 1996;98:2739–45.PubMedCrossRef
50.
Palejwala S, Stein DE, Weiss G, et al. Relaxin positively regulates matrix metalloproteinase expression in human lower uterine segment fibroblasts using a tyrosine kinase signaling pathway. Endocrinology. 2001;142:3405–13.PubMedCrossRef
51.
Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem. 1990;265:10681–5.PubMed
52.
Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85:906–11.PubMed
53.
Fernandez-Patron C, Radomski MW, Davidge ST. Role of matrix metalloproteinase-2 in thrombin-induced vasorelaxation of rat mesenteric arteries. Am J Physiol Heart Circ Physiol. 2000;278:H1473–1479.PubMed
54.
Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17:768–74.PubMedCrossRef
55.
Jeyabalan A, Kerchner LJ, Fisher MC, et al. Matrix metalloproteinase-2 activity, protein, mRNA, and tissue inhibitors in small arteries from pregnant and relaxin-treated nonpregnant rats. J Appl Physiol. 2006;100:1955–63.PubMedCrossRef
56.
Kelly BA, Bond BC, Poston L. Aortic adaptation to pregnancy: elevated expression of matrix metalloproteinases-2 and −3 in rat gestation. Mol Hum Reprod. 2004;10:331–7.PubMedCrossRef
57.
Danielson LA, Welford A, Harris A. Relaxin improves renal function and histology in aging Munich Wistar rats. J Am Soc Nephrol. 2006;17:1325–33.PubMedCrossRef
58.
van Eijndhoven HW, Janssen GM, Aardenburg R, et al. Mechanisms leading to increased vasodilator responses to calcitonin-gene-related peptide in mesenteric resistance arteries of early pregnant rats. J Vasc Res. 2008;45:350–6.PubMedCrossRef
59.
• McGuane JT, Danielson LA, Debrah JE, et al. Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension. 2011;57:1151–60. This article is one of the latest in a series further elucidating the mechanisms of relaxin-induced “sustained” vasodilatory responses. It is significant because angiogenic growth factors are shown to be involved as molecular intermediates. The additional findings that “sustained” relaxin-induced vasodilation is observed in rat and mouse small renal arteries and human subcutaneous arteries, with similar underlying molecular mechanisms, suggest some degree of species conservation, perhaps underscoring the biologic importance of the hormone. PubMedCrossRef
60.
Jeyabalan A, Novak J, Doty KD, et al. Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin. Endocrinol. 2007;148:189–97.CrossRef
61.
Novak J, Conrad KP. Small renal arteries isolated from ETB receptor deficient rats fail to exhibit the normal maternal adaptation to pregnancy [abstract]. FASEB J. 2004;18:32.
62.
Debrah JE, Agoulnik A, Conrad KP. Changes in arterial function by chronic relaxin infusion are mediated by the leucine rich repeat G coupled Lgr7 receptor [abstract]. Reprod Sci. 2008;15(1 Suppl):217A.
63.
Fisher C, MacLean M, Morecroft I, et al. Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation. 2002;106:292–5.PubMedCrossRef
64.
• McGuane JT, Debrah JE, Sautina L, et al. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology. 2011;152:2786–96. This publication investigates mechanisms of relaxin-induced “rapid” vasodilation. Once again, the finding that “rapid” relaxin-induced vasodilation is observed in rat and mouse small renal arteries and human subcutaneous arteries, and the similarity of the underlying molecular mechanisms (at least as tested in the rat and human) suggest some degree of species conservation, perhaps underscoring the biologic importance of the hormone. PubMedCrossRef
65.
Novak J, Parry LJ, Matthews JE, et al. Evidence for local relaxin ligand-receptor expression and function in arteries. FASEB J. 2006;20:2352–62.PubMedCrossRef
66.
McGuane JT, Parry LJ. Relaxin and the extracellular matrix: molecular mechanisms of action and implications for cardiovascular disease. Expert Rev Mol Med. 2005;7:1–18.PubMedCrossRef
67.
Samuel CS. Relaxin: antifibrotic properties and effects in models of disease. Clin Med Res. 2005;3:241–9.PubMedCrossRef
68.
Samuel CS, Du XJ, Bathgate RA, Summers RJ. ‘Relaxin’ the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol Ther. 2006;112:529–52.PubMedCrossRef
69.
Lekgabe ED, Kiriazis H, Zhao C, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension. 2005;46:412–8.PubMedCrossRef
70.
Samuel CS, Hewitson TD, Zhang Y, Kelly DJ. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology. 2008;149:3286–93.PubMedCrossRef
71.
Du XJ, Xu Q, Lekgabe E, et al. Reversal of cardiac fibrosis and related dysfunction by relaxin. Ann N Y Acad Sci. 2009;1160:278–84.PubMedCrossRef
72.
Samuel CS, Cendrawan S, Gao XM, et al. Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest. 2011;91:675–90.PubMedCrossRef
73.
• Xu Q, Chakravorty A, Bathgate RA, et al. Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension. 2010;55:1260–6. This work provides evidence for relaxin’s antifibrotic properties in the setting of established vascular fibrosis (senescent spontaneously hypertensive rats) and demonstrates the beneficial functional effects of the reduction in vascular fibrosis: increased in vivo global arterial compliance and increased ex vivo passive vascular compliance. PubMedCrossRef
74.
• Debrah DO, Debrah JE, Haney JL, et al. Relaxin regulates vascular wall remodeling and passive mechanical properties in mice. J Appl Physiol. 2011;111:260–71. This work comprehensively evaluates the contributions of vascular geometric and compositional remodeling to the relaxin-induced increase in ex vivo passive vascular compliance.PubMedCrossRef
75.
• Chan SL, Cipolla MJ. Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-γ. FASEB J. 2011;25:3229–39. This report is important because it implicates PPARγ as a molecular mediator of relaxin-induced arterial remodeling. PubMedCrossRef
76.
Cipolla MJ, Sweet JG, Chan SL. Cerebral vascular adaptation to pregnancy and its role in the neurological complications of eclampsia. J Appl Physiol. 2011;110:329–39.PubMedCrossRef
77.
Pagani M, Mirsky I, Baig H, et al. Effects of age on aortic pressure-diameter and elastic stiffness-stress relationships in unanesthetized sheep. Circ Res. 1979;44:420–9.PubMed
78.
Gandley RE, Griggs KC, Conrad KP, McLaughlin MK. Intrinsic tone and passive mechanics of isolated renal arteries from virgin and late-pregnant rats. Am J Physiol. 1997;273:R22–27.PubMed
79.
Reddy UM, Wapner RJ, Rebar RW, Tasca RJ. Infertility, assisted reproductive technology, and adverse pregnancy outcomes: executive summary of a National Institute of Child Health and Human Development workshop. Obstet Gynecol. 2007;109:967–77.PubMedCrossRef
80.
Davison JM, Homuth V, Jeyabalan A, et al. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol. 2004;15:2440–8.PubMedCrossRef
81.
Brecht A, Bartsch C, Baumann G, et al. Relaxin inhibits early steps in vascular inflammation. Regul Pept. 2011;166:76–82.PubMedCrossRef
82.
Segal MS, Sautina L, Li S et al. Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood 2011; in press.
83.
Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–58.PubMed
84.
Weiss G, Teichman S, Stewart D, et al. A randomized, double-blind, placebo-controlled trial of relaxin for cervical ripening in post-delivery date pregnancies. Ann N Y Acad Sci. 2009;1160:385–6.PubMedCrossRef
85.
Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a “set up” for vascular disease. Circulation. 2003;107:139–46.PubMedCrossRef
Metadaten
Titel
Effects of Relaxin on Arterial Dilation, Remodeling, and Mechanical Properties
verfasst von
Kirk P. Conrad
Sanjeev G. Shroff
Publikationsdatum
01.12.2011
Verlag
Current Science Inc.
Erschienen in
Current Hypertension Reports / Ausgabe 6/2011
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-011-0231-x

Weitere Artikel der Ausgabe 6/2011

Current Hypertension Reports 6/2011 Zur Ausgabe

Special Situations in the Management of Hypertension (Theodore Kotchen, Section Editor)

Immune Mechanisms in Hypertension

Mediators, Mechanisms, and Pathways in Tissue Injury (Heinrich Taegtmeyer and Steven A. Atlas, Section Editors)

Heart Failure Associated with Sunitinib: Lessons Learned from Animal Models

Mediators, Mechanisms in Tissue Injury (Heinrich Taegtmeyer, Steven Atlas, Section Editors)

The Roles of Integrins in Mediating the Effects of Mechanical Force and Growth Factors on Blood Vessels in Hypertension

Mediators, Mechanisms in Tissue Injury (Heinrich Taegtmeyer, Steven A. Atlas, Section Editors)

Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated Cardiotoxicity

Clinical Trial Report

Salivary Cortisol Predicts Cardiovascular Mortality

Invited Commentary

Improvement of Sodium Status to Optimize the Efficacy of Renin-Angiotensin System Blockade

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise